CReST showed that stenting as a bridge to surgery reduces stoma formation without detrimental effects in colon cancer patients with left-sided colonic obstruction #ICTD2023@BJSurgery https://t.co/QAQj3IWNZk
@RePHILL_trial was our first trial in a prehospital setting and with the air ambulance service. Randomising 432 adults with trauma related haemorrhagic shock the trial did not show prehospital PRBC–LyoPlas resuscitation was superior to sodium chloride @TheLancetHaem#ICTD2023
Recruiting from 80 hospitals in 7 global south countries, @CheetahRct found that 1 in 8 surgical site infections could be prevented by changing gloves and instruments before fascial closure for abdominal surgery @TheLancet@NIHR_GSU#ICTD2023 https://t.co/Umt61OslaQ
The @STOPACEi_trial showed that in people with advanced and progressive chronic kidney disease, discontinuation of RAS inhibitors was not associated with difference in rate of decrease in kidney function measured using eGFR @NEJM#ICTD2023 https://t.co/NE9iPglLLA
@CSTICH_Trial, which recruited 2049 women undergoing cervical cerclage, showed that a monofilament suture was not associated with improved pregnancy loss rates compared with a braided suture thread #ICTD2023@TheLancet https://t.co/GoQCeefJCG
Jointly delivered with @CRCTU the MSc in Clinical Trials provides a foundation to clinical trials covering theoretical & practical aspects of the design, conduct, analysis and interpretation of trials. Developed for a broad audience from industry, NHS Trusts & academia #ICTD2023
Published in @JCO_ASCO, FOxTROT showed that six weeks of preoperative chemotherapy for operable colon cancer can be delivered safely and provides better 2-year disease control #ICTD2023
https://t.co/8P6KCnqqpq
@Gem3Study showed in women who have a tubal ectopic pregnancy, combination treatment of gefitinib and methotrexate was not associated with a difference in need for surgical intervention compared to those who have methotrexate only @TheLancet#ICTD2023 https://t.co/jDp2kfy9eZ
@basil_trials showed that a best endovascular treatment first revascularisation strategy was associated with a better amputation-free survival over the vein bypass group for patients with chronic limb threatening ischaemia @TheLancet#ICTD2023 https://t.co/qiGA6bwVGH
Funded by @gatesfoundation, the @EmotiveTrial cluster randomised trial showed an immense 60% reduction in severe postpartum haemorrhage after vaginal delivery, reducing the risk of haemorrhage-related maternal death @NEJM#ICTD2023 https://t.co/qifx13QwBA
BCTU, a UKCRC registered trials unit was 25 years old in 2022. Clinical Trial Units play a key role in the design and delivery of clinical trials. To celebrate #ClinicalTrialsDay we will be tweeting about some of the trials we have delivered over the past 12 months.
Proud beyond words of the work of colleagues from @unibirmingham
@unibirm_MDS @IMSR_UoB @UoB_IAHR Partnering with the @WHO and @gatesfoundation , implementation of the intervention would have huge impact .
I’m very encouraged by the E-MOTIVE Trial results released today at #IMNHC2023 to treat postpartum hemorrhage, the #1 cause of maternal mortality. This new approach led by @unibirmingham and @WHO could drastically improve women’s chances of surviving childbirth globally. https://t.co/5rLoflpcv0
🥁🥁🥁Tweetorial
FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer
We report that NAC is
✅deliverable and safe
✅led to statistically significant reduction in cancer recurrence than upfront surgery
A 🧵 (1/14)
#crcsm
https://t.co/y1hU6qWdXF
🥁🥁🥁Tweetorial
FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer
We report that NAC is
✅deliverable and safe
✅led to statistically significant reduction in cancer recurrence than upfront surgery
A 🧵 (1/14)
#crcsm
https://t.co/y1hU6qWdXF
📢 News: FOxTROT, a trial we funded, has shown that starting chemotherapy before surgery, instead of after, can significantly cut the risk of colon cancer coming back. The findings could change how doctors treat colon cancer in the NHS and around the world https://t.co/kwfo5LX9M2
But that's not all! FOxTROT-2 and 3 are currently active and further researching neoadjuvant chemotherapy in colon cancer. You can find out more at @FoxtrotStudy@LeedsCTRU
FOxTROT-1 trial results have been released by @JCO_ASCO!
✅Pre-operative chemotherapy for locally advanced operable colon cancer is safe
✅Improved histopathological & oncological outcomes
✅Reduced 2-year recurrence
https://t.co/d5Due1ohJU